AbCellera Biologics (ABCL)
(Delayed Data from NSDQ)
$3.76 USD
+0.13 (3.58%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $3.76 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth A Momentum F VGM
Price, Consensus and EPS Surprise
ABCL 3.76 +0.13(3.58%)
Will ABCL be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ABCL based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ABCL
AbCellera Biologics Inc. (ABCL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Beyond Air, Inc. (XAIR) Reports Q3 Loss, Misses Revenue Estimates
ABCL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Techne (TECH) Q2 Earnings and Revenues Lag Estimates
Is AbCellera Biologics (ABCL) Outperforming Other Medical Stocks This Year?
Earnings Preview: AbCellera Biologics Inc. (ABCL) Q3 Earnings Expected to Decline
Other News for ABCL
Clinical-Stage BioTech Drug Stocks Portfolio Went Down 9% Last Week
AbCellera management to meet with Truist
AbCellera management to meet with Truist
The 10 Stocks In The Clinical-Stage BioTech Drug Stocks Index Are Down 4% YTD
AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024